GPS Wealth Strategies Group LLC Purchases 185 Shares of DexCom, Inc. (NASDAQ:DXCM)

GPS Wealth Strategies Group LLC increased its position in DexCom, Inc. (NASDAQ:DXCM) by 13.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,587 shares of the medical device company’s stock after buying an additional 185 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in DexCom were worth $123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. NewEdge Advisors LLC grew its holdings in DexCom by 18.3% in the second quarter. NewEdge Advisors LLC now owns 9,020 shares of the medical device company’s stock worth $1,023,000 after purchasing an additional 1,393 shares during the period. B. Riley Wealth Advisors Inc. lifted its position in shares of DexCom by 4.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after acquiring an additional 162 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of DexCom in the second quarter worth about $1,395,000. SG Americas Securities LLC raised its stake in DexCom by 52.5% during the third quarter. SG Americas Securities LLC now owns 71,023 shares of the medical device company’s stock valued at $4,761,000 after purchasing an additional 24,442 shares in the last quarter. Finally, Czech National Bank boosted its stake in shares of DexCom by 7.7% during the 3rd quarter. Czech National Bank now owns 81,632 shares of the medical device company’s stock worth $5,473,000 after purchasing an additional 5,850 shares during the period. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,342 shares of company stock valued at $3,628,069. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Oppenheimer dropped their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Royal Bank of Canada decreased their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $98.41.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $87.05 on Tuesday. The firm has a market capitalization of $34.00 billion, a PE ratio of 52.13, a PEG ratio of 2.23 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The business’s 50 day moving average is $80.77 and its 200-day moving average is $75.94.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.